These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28029009)

  • 21. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
    Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated Genome-Wide Analysis of an Isogenic Pair of
    Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
    Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Morrissey I; Magnet S; Hawser S; Shapiro S; Knechtle P
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
    Ortiz de la Rosa JM; Nordmann P; Poirel L
    J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
    Poirel L; Ortiz De La Rosa JM; Kieffer N; Dubois V; Jayol A; Nordmann P
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224535
    [No Abstract]   [Full Text] [Related]  

  • 30. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
    Rolston KVI; Gerges B; Shelburne S; Aitken SL; Raad I; Prince RA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
    Walkty A; Karlowsky JA; Adam H; Baxter M; Lagacé-Wiens P; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5707-9. PubMed ID: 23939895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Van Dalem A; Herpol M; Echahidi F; Peeters C; Wybo I; De Wachter E; Vandamme P; Piérard D
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China.
    Zhou M; Cheng J; Liu Y; Hu Y; Liu Y; Lu J; Zhang S; Yu Y; Huang X; Yang Q; Liao K; Jin Y; Huang W; Feng X; Yang Q; Xu Y
    Clin Infect Dis; 2018 Nov; 67(suppl_2):S206-S216. PubMed ID: 30423043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).
    Sader HS; Castanheira M; Mendes RE; Flamm RK
    J Antimicrob Chemother; 2018 Nov; 73(11):3053-3059. PubMed ID: 30060117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
    Flamm RK; Stone GG; Sader HS; Jones RN; Nichols WW
    J Chemother; 2014 Dec; 26(6):333-8. PubMed ID: 24125508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H
    J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409
    [No Abstract]   [Full Text] [Related]  

  • 39. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011).
    Flamm RK; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):233-8. PubMed ID: 25128477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients.
    Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM
    J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.